Maze Therapeutics Inc
Research Maze Therapeutics Inc (MAZE) on Bullrun: market cap USD 1.69B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMAZE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.69B
- Financial periodQ1 2026
- RevenueUSD 20.00M
- Net income-USD 24.21M
- Free cash flow-USD 39.21M
Valuation Snapshot
latest market cap is USD 1.69B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 131.12M | -USD 112.73M | n/a | -3.05 | USD 189.25M | USD 23.31M | USD 354.97M |
| FY2024 | USD 167.50M | USD 52.23M | USD 74.81M | n/a | 1.25 | USD 196.81M | USD 26.63M | -USD 311.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.69B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.04B | n/a | n/a | n/a |
About Maze Therapeutics Inc
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Maze Therapeutics Inc's market cap?
Maze Therapeutics Inc's market capitalization is USD 1.69B.
What does Maze Therapeutics Inc do?
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.